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Abstract
Background: Literature shows the effects of type of cancer and/or anticancer treatment on live birth percentages
and/or pregnancy and neonatal complications in female cancer survivors. However, studies analyzing the obstetric
and offspring risks of the morbid conditions associated with previous anti-cancer treatments are missing. The
present review aims to uncover these risks.
Methods: A literature search based on publications up to March 2016 identified by PubMed and references
cited in relevant articles.
Results: The morbid conditions associated with prior anticancer treatments including chemotherapy, radiotherapy,
surgery, and/or hematopoietic stem-cell transplant may induce not only obstetric and neonatal complications but also
long-term effects on offspring. Whereas some risks are predominantly evidenced in untreated women others
are observed in both treated and untreated women. These risks may be superimposed on those induced by
the current women’s trend in Western societies to postpone maternity.
Conclusions: Medical professionals should be aware and inform female cancer survivors wishing to have a child not
only of the short- and long-term risks to themselves and their prospective offspring of previous anticancer treatments,
fertility-preservation technologies, and pregnancy itself, but also of those risks linked to the morbid conditions induced
by prior anticancer treatments. Once female cancer survivors wishing to have a child have been properly informed
about the risks of reproduction, they will be best placed to make decisions of whether or not to have a biological or
donor-conceived child. In addition, when medical professionals be aware of these risks, they will be also best placed to
provide appropriate treatments before/during pregnancy in order to prevent or alleviate the impact of these morbid
conditions on maternal and offspring health.
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Background
The recent advances in anticancer treatments includ-
ing chemotherapy, radiotherapy, surgery, and/or
hematopoietic stem-cell transplant have increased per-
centages of remission and survival after treatment (for
review, see Tschudin and Bitzer [1]). Despite these
improvements, anticancer treatments still represent an
immediate threat to health as well as later health
complications clinically evidenced years or even
decades after completion of therapy. In fact, it is esti-
mated that approximately two thirds of childhood
cancer survivors experience at least one chronic med-
ical problem. The other one third suffers from severe
or life-threatening complications 30 years after diag-
nosis of their primary cancer, mostly due to adverse
cardiovascular events, pulmonary dysfunction, or sec-
ond malignancies including leukemias and a variety of
solid tumors involving the thyroid gland, breast, cer-
vix, corpus of the uterus, and ovaries (for reviews, see
Barnes and Chemaitilly [2] and Travis et al. [3]).
Another important issue linked to anticancer treat-
ments is the temporary or permanent loss of fertility
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(for review, see Knopman et al. [4]). We should note
that most female cancer survivors desire to have biological
children and many of them, especially childless women,
may feel cancer-related infertility as an emotionally dis-
tressing and devastating health problem [5]. This distress,
however, may be attenuated if female cancer patients were
properly informed about the risks to fertility of anticancer
therapies and offered fertility preservation options prior
starting any treatment [6]. Indeed, a number of medical
approaches to preserve fertility before treatment begins
are being currently developed and implemented. These
approaches include the use of gonadotropin releasing
hormone analogs (GnRHas) for ovarian suppression
during chemotherapy, fertility-sparing surgery, transvagi-
nal immature oocyte retrieval and subsequent in-vitro
maturation, oocyte cryopreservation for future in-vitro
fertilization (IVF), cryopreservation of embryos after either
IVF or intracytoplasmic sperm injection, and ovarian
tissue banking for future orthotopic or heterotopic auto-
transplantation, xeno-transplantation into immunodefi-
cient animals, or in-vitro follicular maturation and IVF
(for reviews, see West et al. [7], Dittrich et al. [8], Smyth
et al. [9], and Lambertini et al. [10]). Of note, some of
these procedures including ovarian tissue cryopreservation
[11], in-vitro maturation [12], and ovarian suppression
during chemotherapy with GnRHas [13] are still nowadays
classified as experimental/investigational. Consequently,
they should not be represented or marketed to patients as
established or routine medical procedures [14]. They
should be offered to patients only in a research setting
with institutional review board oversight [15].
In addition to the risk to fertility, female cancer pa-
tients should be informed before starting any anticancer
treatment about the potential short- and long-term risks
of anticancer therapy and fertility-preservation practices
including the risk posed by fertility treatment and the
possibility of reintroducing malignant tumors cells after
transplantation of cryopreserved ovarian tissue [15].
Cancer patients should know that chemotherapy and
radiotherapy have the potential to induce germ cell mu-
tations that may lead to congenital anomalies and/or
genetic disease in the next generation, particularly in
those cancer survivors who have not undergone a previ-
ous fertility preservation procedure. They should be in-
formed about this possibility despite literature shows
that neither chemotherapy nor radiotherapy is associated
with (1) germline minisatellite mutations in survivors of
childhood and young adult cancer [16]; and (2) single
gene disorders, chromosomal defects, mitochondrial
DNA mutations, altered sex ratio (suggesting no in-
creased incidence of X-linked mutations), congenital ab-
normalities or adventitious cancer in offspring [17–19]
(for reviews, see Knopman et al. [4], Hudson [20],
Lawrenz et al. [21], and Nakamura et al. [22]). Cancer
patients should know that the reported absence of
effect of anticancer therapies on offspring genetic/
chromosomal/congenital anomalies is likely due, at
least in part, to the strong selection against most of
the common chromosomal abnormalities present dur-
ing pre- and post-implantation embryo/fetal develop-
ment [23]. Accordingly, most embryos/fetuses with
chromosomal anomalies may be lost before or shortly
after implantation, even before women are aware that
they are pregnant. Not surprisingly, literature shows
that female cancer survivors without a prior fertility
preservation procedure are substantially less likely to
achieve a pregnancy and to have live births than their
siblings or the general population (for reviews, see
Knopman et al. [4] and Lawrenz et al. [21]). In
addition, most birth defects are multifactorial in
origin with clear interactions among genetics, epigen-
etics, maternal hormonal levels, and environmental
exposures (e.g., medications, folate levels, nutrition,
obesity, smoking, alcohol, pollutants, etc.) (for review,
see Webber et al. [24]). This multifactorial origin of
birth defects may dilute any existing association of
anticancer therapies on offspring congenital anomalies.
Notwithstanding, circumstantial evidence suggests that
human immature resting oocytes compared with mouse
oocytes are relatively resistant to radiation, not only in
terms of cell killing but also in terms of induction of mu-
tations (for review, see Nakamura et al. [22]).
After treatment and remission, female survivors
wishing to have a child should be aware of other bio-
logical risks not only to themselves but also to their
prospective offspring before making the decision to
reproduce, irrespectively of whether they previously
used fertility-preservation technologies or not. In par-
ticular, the potential risks posed by pregnancy on
cancer recurrence (especially in breast cancer, endometrial
cancer, and malignant melanoma), the difficulty in detect-
ing cancer during pregnancy (particularly in breast cancer
and endometrial cancer), and transmission of hereditary
cancer syndromes (for review, see Matthews et al. [25]).
Although literature evidences the effects of type of can-
cer and/or anticancer treatment on live birth percentages
and/or pregnancy and neonatal complications (for re-
views, see Knopman et al. [4], Hudson [20], and Lawrenz
et al. [21]), studies showing the obstetric and offspring
risks of the morbid conditions associated with previous
anti-cancer treatments are missing. In order to fill this
gap, the present review aims to uncover and highlight the
obstetric and offspring risks of the morbid conditions as-
sociated with previous anti-cancer treatments.
Methods
A literature search based on publications up to March 2016
identified by PubMed database searches using the following
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search terms: female cancer survivors, obstetric and neo-
natal risks, long-term risks, offspring, hyperprolactinemia,
hypopituitarism, hypothyroidism, hyperthyroidism, primary
ovarian insufficiency, obesity, overweight, hyperglycemia,
insulin resistance, metabolic syndrome, diabetes mellitus,
cardiovascular disease, obstructive lung disease, restrictive
lung disease, decreased pulmonary diffusion capacity,
chronic kidney disease, chronic hypertension, uterine dam-
age, and low bone mineral density. In addition, a hand
search was done to explore the references cited in the pri-
mary articles. Only articles (whenever possible systematic
reviews and meta-analyses) published in English were
included.
Results
Table 1 shows the potential obstetric and offspring risks
of morbid conditions associated with prior anticancer
treatment. Note that whereas some risks are predomin-
antly evidenced in untreated women others are observed
in both treated and untreated women. For instance, the
increased risk of seizure (neonatal seizure, febrile seiz-
ure, and epilepsy), autism spectrum disorders, and
attention-deficit hyperactivity disorder in offspring as-
sociated with maternal hypothyroidism or hyperthy-
roidism is mainly observed when the mother is first
time diagnosed and treated for thyroid dysfunction
after birth of the child, not before/during pregnancy
(for review, see Andersen et al. [26]). Such a circum-
stance suggests that diagnosis and treatment of thyroid
dysfunction before/during pregnancy may prevent or alle-
viate the effects of maternal thyroid disease on early brain
development (for review, see Andersen et al. [26]).
Likewise, (1) untreated hyperprolactinemia may be a risk
factor for ectopical pregnancy [27]; (2) uncontrolled overt
hyperthyroidism is associated with increased risk of thy-
roid storm, maternal congestive heart failure, miscarriage,
stillbirth, preterm delivery, pre-eclampsia, low birth
weight, intrauterine growth restriction, and fetal/neonatal
thyroid dysfunction (for review, see Pearce [28]); (3) un-
treated euthyroid pregnant women with detectable thyroid
autoantibodies display higher risks of miscarriage and pre-
term delivery than treated women (for systematic review,
see Thangaratinam et al. [29]); and (4) tight glycemic con-
trol as well as dietary antioxidant supplementation during
the preconception period and during the first trimester of
pregnancy can prevent diabetes-associated birth defects
and pregnancy complications (for review, see Ornoy et al.
[30]). Notwithstanding, the level of glycemic control and
glycemic threshold in pregnancy for preventing offspring
complications later in life is still unknown (for review, see
Hiersch and Yogev [31]).
On the contrary, chronic hypertension is associated
with increased risk of adverse obstetrical and neonatal
outcomes including pre-eclampsia, placental disorders,
gestational diabetes, threatened abortion, preterm deliv-
ery, low birth weight, and congenital malformations,
irrespectively of whether women are treated or not dur-
ing pregnancy (for reviews, see Czeizel and Bánhidy
[32] and Batemanet al. [33]). Of note, pregnant women
suffering from chronic hypertension treated with
antihypertensive drugs display ORs as high as 6.0 for
pre-eclampsia, 2.3 for placental disorders, and 2.2 for
gestational diabetes compared with control pregnant
women without any type of hypertension (for review,
see Czeizel and Bánhidy [32]). In addition, there are
morbid conditions associated with prior anticancer
therapies displaying problematic, controversial, or no
treatment at all. For instance, obesity, restrictive lung
disease, decreased pulmonary diffusion capacity, and
uterine damage are not easily managed in clinical prac-
tice. Furthermore, many drugs prescribed for heart dis-
ease have teratogenic effects. Therefore, medication
should be reviewed prior to pregnancy (for review, see
Emmanuel and Thorne [34]).
Finally, we cannot ignore that maternal age at child-
birth is steadily rising in many Western populations,
and female cancer survivors are not an exception to
this general trend [35]. The resulting obstetric and
offspring risks associated with postponed maternity
(for reviews, see Usta and Nassar [36], Nassar and
Usta [37], and Sauer [38]) may be superimposed on
those already present in cancer survivors. Importantly,
the extra risks posed by delayed motherhood may not
be prevented by applying fertility preservation strategies
such as oocyte/embryo/ovarian tissue cryopreservation at
younger ages. In fact, reciprocal ovarian transplants be-
tween young and old female mice show that the risk of
congenital heart disease associated with advanced mater-
nal age is not conferred by oocytes, but by the mother’s
age [39]. Interestingly, this risk is modified by the mother’s
genetic background and can be mitigated (but not elimi-
nated entirely) by maternal voluntary (ad libitum) exercise
beyond a threshold number of days before birth date,
whether exercise begins at a young age or later in life [39].
Conclusions
The present review shows that the morbid condi-
tions associated with prior anticancer treatments in-
cluding chemotherapy, radiotherapy, surgery, and/or
hematopoietic stem-cell transplant may induce obstetric
and neonatal complications as well as long-term effects on
offspring. Of note, whereas some risks are predominantly
evidenced in untreated women others are observed in
both treated and untreated women. These risks may be
superimposed on those induced by the current women’s
trend in Western societies to postpone maternity. Medical
professionals should be aware and inform female cancer
survivors wishing to have a child of the short- and long-
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Table 1 Potential obstetric and offspring risks of morbid conditions associated with prior anticancer treatments including
chemotherapy, radiotherapy, surgery, and/or hematopoietic stem-cell transplant
Morbid conditions associated with prior
anticancer treatments
Potential obstetric and neonatal risksa Potential long-term risks to offspringa
Endocrine disorders (for review, see Barnes and
Chemaitilly [2]).
Hypothalamic-pituitary axis: hyperprolactinemia
and deficiencies in growth hormone (GH),
luteinizing hormone (LH), follicle-stimulating
hormone (FSH), adrenocorticotropic hormone
(ACTH), thyroid stimulating hormone (TSH), and
antidiuretic hormone (ADH).
- Obstetric complications are rare in
hyperprolactinemic women treated or untreated
with bromocriptine, although untreated
hyperprolactinemia may be a risk factor for
ectopical pregnancy (25 %, 4/78 vs. 5 %, 6/25 in
bromocriptine-treated pregnancies (P = 0.017)
[27].
- Hyperprolactinemia may lead to galactorrhea
and nipple tenderness which are not suitable for
breastfeeding (for review, see Du et al. [40]).
- Maternal hypopituitarism is associated with
increased risk of abortion during early gestation,
anemia, pregnancy-induced hypertension,
placental abruption, premature birth, cesarean
birth, and postpartum uterine inertia leading to
postpartum hemorrhage (for review, see Du et
al. [40]).
- Thyroid gland: primary hypothyroidism with
elevated plasma TSH levels and either normal or
low levels of free thyroxine (T4),
hyperthyroidism, or autoimmune induced
thyroid disease (note that the presence of
thyroid antibodies does not necessarily lead to
hypothyroidism in the context of hematopoietic
stem-cell transplant).
- Pregnant women with subclinical
hypothyroidism (elevated plasma TSH levels and
normal free T4) have increased risk of
miscarriage, gestational diabetes, preterm
delivery, and placental abruption (for review, see
Pearce [28]). Likewise, maternal overt
hypothyroidism (elevated plasma TSH levels and
low free T4) is associated with miscarriage,
stillbirth, gestational hypertension, preterm
delivery, and low birth weight (for review, see
Pearce [28]).
- Maternal subclinical or overt hypothyroidism is
associated with decreased child intelligence (for
review, see Pearce [28]). Maternal
hypothyroidism is also associated with increased
risk of neonatal seizure [adjusted hazard ratio
(HR):1.08, 95 % confidence interval (CI): 1.02-
1.15], febrile seizure (adjusted HR: 1.21, 95 % CI:
1.10-1.32), and epilepsy (adjusted HR: 1.22, 95 %
CI: 1.06-1.40); childhood autism spectrum
disorders (adjusted HR: 1.30, 95 % CI:1.11-1.53);
and adolescence and young adulthood
psychiatric disorders (adjusted HR for use of
antipsychotics: 1.22, 95 % CI: 1.03-1.44; and
adjusted HR for use of anxiolytics: 1.23, 95 % CI:
1.03-1.48) (for review, see Andersen et al. [26]).
- Pregnant women with subclinical
hyperthyroidism is not associated with adverse
maternal or fetal outcomes (for review, see
Pearce [28]). In contrast, uncontrolled overt
hyperthyroidism during pregnancy is associated
with increased risk of thyroid storm, maternal
congestive heart failure, miscarriage, stillbirth,
preterm delivery, pre-eclampsia, low birth
weight, intrauterine growth restriction, and fetal/
neonatal thyroid dysfunction (for review, see
Pearce [28]).
- Maternal hyperthyroidism increases the risk of
epilepsy (adjusted HR: 1.20, 95 % CI: 1.09-1.32)
and attention-deficit hyperactivity disorder
(adjusted HR: 1.18, 95 % CI: 1.03-1.36) (for review,
see Andersen et al. [26]).
- Autoimmune hypo- or hyperthyroidism during
pregnancy is associated with the same
obstetrical and neonatal risks posed by non-
autoimmune hypo- or hyperthyroidism (see
above). In addition, euthyroid pregnant women
with detectable thyroid autoantibodies display
higher risk of miscarriage [in cohort studies,
random effects odds ratio (OR):3.90, 95 % CI:
2.48-6.12; in case-control studies, random effects
OR:1.80, 95 % CI: 1.25-2.60] and preterm delivery
(in cohort studies, random effects OR: 2.07, 95 %
CI: 1.17-3.68) (for systematic review, see
Thangaratinam et al. [29]). Notwithstanding,
treatment with levothryroxine reduces the risk
of miscarriage [relative risk (RR):0.48, 95 %
CI:0.25-0.92] and preterm delivery (RR: 0.31, 95 %
- Autoimmune hypo- or hyperthyroidism during
pregnancy is associated with the same long-
term risks to offspring posed by non-
autoimmune hypo- or hyperthyroidism (see
above). Furthermore, children of euthyroid
pregnant women with elevated titers of thyroid
peroxidase autoantibody (TPOAb) are at risk for
transient hyperthyroxinemia one week after
birth (the values of free T4 are, however,
normalized after 15 days) [48] and impaired
psychomotor development at 5 years of age
(adjusted OR for the scores on the General
Cognitive Scale: 10.5, 95 % CI: 3–34) (for review,
see Dallas [49]). Transplacentally-transmitted
TPOAb positivity at birth is also associated with
increased incidence of autoimmune thyroiditis
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Table 1 Potential obstetric and offspring risks of morbid conditions associated with prior anticancer treatments including
chemotherapy, radiotherapy, surgery, and/or hematopoietic stem-cell transplant (Continued)
CI: 0.11-0.90) (for systematic review, see
Thangaratinam et al. [29]).
during childhood and adolescence (adjusted OR:
4.12, 95 % CI: 1.79-9.50) [50].
- Gonads: acute ovarian insufficiency (i.e.,
women do not experience a recovery of their
ovarian function after finishing cancer
treatments) or primary ovarian insufficiency
(POI), previously called premature ovarian failure
or premature or early menopause (i.e., women
resume pubertal development or menstrual
cycles after finishing cancer treatments but
experience ovarian failure before the age of
40 years).
- In contrast to natural menopause, women
diagnosed with POI may undergo unpredictable
ovarian function leading to intermittent and
unpredictable menses in 50 % of cases.
Pregnancy and delivery in women with POI are
unlikely and rare (for review, see Tarín et al. [41]).
- Body composition: survivors of acute
lymphoblastic leukemia and brain tumors have
higher risks of obesity and overweight.
- Pregnant women with obesity have higher risk
of gestational diabetes (OR: 3.76, 95 % CI: 3.31-
4.28 for women with body mass index (BMI) >
29.9 kg m−2), gestational hypertension (4.5-8.7
times more likely than normal weight women),
pre-eclampsia (pooled RR: 2.68, 95 % CI: 2.40-
3.00 for women with BMI 30–34.9 kg m−2),
antenatal (OR: 1.43, 95 % CI: 1.27-1.61) and
postnatal (OR: 1.30, 95 % CI: 1.20-1.42)
depression, antenatal anxiety (OR: 1.41, 95 % CI:
1.10-1.80), instrumental-vaginal (OR: 1.17, 95 %
CI: 1.13-1.21) and cesarean birth (ORs from 2.01,
95 % CI: 1.87-2.15 to 2.36, 95 % CI:2.15-2.59), and
surgical site infection than pregnant women of
healthy weight. In addition, maternal obesity is
associated with higher risk of congenital
anomalies, preterm birth (adjusted OR: 1.33,
95 % CI: 1.12-1.57 for women with BMI≥
35 kg m−2), large-for-gestational-age babies
(above the 90th centile) (OR: 2.08, 95 % CI:1.95-
2.23), miscarriage (pooled OR: 1.31, 95 % CI:
1.18-1.46 for women with BMI≥ 28 kg m−2),
fetal death (RR: 1.34, 95 % CI: 1.22-1.47 for
women with BMI≥ 30 kg m−2), stillbirth
(adjusted OR: 1.6, 95 % CI:1.35-1.95 for women
with BMI≥ 30 kg m−2), birth over 41–42 weeks’
gestation, induction of labor, failure to progress
in labor, post-partum hemorrhage, longer
duration of hospital stay, neonatal intensive care
unit admission, lower breastfeeding initiation
incidence (ORs from 1.19 to 3.65), and shorter
breastfeeding duration (HRs from 1.24 to 2.54)
[42] (for systematic review, see Marchi et al.
[43]).
- Maternal obesity is associated with
cardiovascular and metabolic disorders, obesity,
childhood asthma and wheezing, cognitive
development deficits, attention-deficit
hyperactivity disorder, cancer, and greater all-
cause mortality (for review, see Wilson and
Messaoudi [51]).
- Glucose metabolism: insulin resistance,
metabolic syndrome, and diabetes mellitus.
- Maternal diabetes increases the risk of
congenital anomalies affecting any developing
organ system, although cardiovascular and
neural tube defects are among the most
frequent anomalies. Furthermore, it increases
the risk of pre-eclampsia, preterm delivery, fetal
macrosomia, low birth weight, and perinatal
mortality [42].
- Children born to diabetic mothers tend to be
overweight and taller, and have increased
incidence of gross and fine motor abnormalities,
attention deficit hyperactivity disorder, learning
difficulties, likely autism spectrum disorder, and
metabolic morbidity later in life (for reviews, see
Hiersch and Yogev [31] and Ornoy et al. [30]).
- Pregnant women with insulin resistance
display increased risk of miscarriage, pre-
eclampsia, and fetal macrosomia, especially in
pregnancies complicated by type 1 diabetes
mellitus [44] (for review, see Gutaj et al. [45]).
Moreover, maternal pregestational type 2
diabetes mellitus (insulin resistance) is associated
with a higher prevalence of birth defects in
offspring [adjusted prevalence ratio (PR): 4.51,
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95 % CI: 2.46-8.29] including cardiovascular,
genitourinary, and musculoskeletal defects [46].
- Women with metabolic syndrome have a
higher risk of pre-eclampsia, preterm delivery or
low birth weight (for review, see Malek [47]).
- Children of mothers with metabolic syndrome
are likely to develop metabolic syndrome and
cardiovascular disease (for review, see Malek
[47]).
Adverse cardiovascular events (for reviews, see
Travis et al. [3] and Ewer and Ewer [52]).
- Left ventricular systolic dysfunction,
cardiovascular disease (pericardial disease,
coronary artery disease, carotid artery occlusive
disease, premature valvular calcification and
dysfunction, conduction abnormalities, and
cerebrovascular disease), cardiac arrhythmias,
and cardiac ischemia.
- Pregnant women suffering from heart diseases
have increased risk of maternal cyanosis, risk of
bleeding due to anticoagulation treatment,
placental hypoperfusion and/or cyanosis, fetal
growth restriction, miscarriage, stillbirth, and
prematurity (for review, see Emmanuel and
Thorne [34]).
Pulmonary dysfunction in childhood cancer
survivors, particularly in women treated with
pulmonary-toxic chemotherapy and survivors
treated with more than 20 Gy chest radiation
[53].
- Restrictive lung disease with reduced lung
volumes as a result of either decreased lung
parenchyma or changes to the chest wall that
may restrict lung parenchyma growth.
- The ability to increase the minute ventilation
during pregnancy may be limited in pregnant
women with restrictive lung disease.
Consequently, they may have difficulty meeting
the increased oxygen demands of late
pregnancy putting the fetus at risk of hypoxic
injury [54].
- Fetal chronic hypoxia induces fetal growth
restriction and programs cardiovascular,
metabolic, and endocrine dysfunction in the
adult offspring (for review, see Giussani et al.
[56]).
- Decreased pulmonary diffusion capacity. - Cancer survivors with decreased pulmonary
diffusion capacity are more likely to report
respiratory symptoms, poor physical functioning,
low energy and increased fatigue than survivors
without diffusion defects [53]. These effects may
be exacerbated during the third trimester of
pregnancy when pulmonary diffusion capacity
decreases compared to non-pregnant women
especially in women living at high altitude [55].
Renal adverse effects (for systematic review, see
Knijnenburg et al. [57]; for review, see Porta et
al. [58]).
- Acute kidney injury, renal insufficiency, chronic
kidney disease, impaired glomerular filtration
rate, proteinuria, electrolyte disturbances,
impaired phosphate tubular regulation,
hypertension, and thrombotic
microangiopathies.
- Pregnant women with chronic kidney disease
and serum creatinine levels > 1.5 mg/dL have
higher risk of gestational deterioration in renal
function. In addition, there is a negative linear
association between maternal proteinuria and
infant birth weight as well as between the
severity of maternal proteinuria and degree of
renal dysfunction and fetal loss (for review, see
Gyamlani and Geraci [59]).
- Treated chronic hypertension in pregnancy is
associated with increased risk of pre-eclampsia
(adjusted OR: 6.0, 95 % CI: 4.7-8.8), placental
disorders (adjusted OR: 2.3, 95 % CI: 1.8-3.1),
gestational diabetes (adjusted OR: 2.2, 95 % CI:
1.4-3.5), threatened abortion (adjusted OR: 1.9,
95 % CI: 1.7-2.1), preterm delivery (adjusted OR:
1.5, 95 % CI: 1.3-1.8), and low birth weight
(adjusted OR: 2.3, 95 % CI: 1.8-2.7) (for review,
see Czeizel and Bánhidy [32]). In addition,
pregnancies complicated by chronic
hypertension are at increased risk of congenital
abnormalities, particularly cardiac malformations
(adjusted OR in treated women: 1.06, 95 % CI:
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term risks to themselves and their prospective offspring
irrespectively of whether they previously used fertility-
preservation technologies or not. These risks not only in-
clude those associated with previous anticancer treatments,
fertility-preservation technologies, and pregnancy itself,
but also those linked to the morbid conditions induced by
prior anticancer treatments. Once female cancer survivors
wishing to have a child have been properly informed about
the risks of reproduction, they will be best placed to make
decisions of whether or not to have a biological or donor-
conceived child. In addition, when medical professionals be
aware of these risks, they will be also best placed to provide
appropriate treatments before/during pregnancy in order
to prevent or alleviate the impact of these morbid condi-
tions on maternal and offspring health.
Abbreviations
ACTH, adrenocorticotropic hormone; ADH, antidiuretic hormone; BMI, body
mass index; CI, confidence interval; FSH, follicle-stimulating hormone; GH,
growth hormone; GnRHa, gonadotropin releasing hormone analog; HR,
hazard ratio; IVF, in-vitro fertilization; LH, luteinizing hormone; OR, odds
ratio; POI, primary ovarian insufficiency; PR, prevalence ratio; RR, relative
risk; T4, thyroxine; TPOAb, thyroid peroxidase autoantibody; TSH, thyroid
stimulating hormone
Table 1 Potential obstetric and offspring risks of morbid conditions associated with prior anticancer treatments including
chemotherapy, radiotherapy, surgery, and/or hematopoietic stem-cell transplant (Continued)
1.4-1.9; adjusted OR in untreated women: 1.5,
95 % CI: 1.3-1.7) (for review, see Bateman et al.
[33]).
Uterine damage (for reviews, see Lawrenz et al.
[21], Wo and Viswanathan [60]; Wallace et al.
[61], and Teh et al. [62]).
- Total-body, flank, abdomen, pelvis or direct
uterine irradiation leads to changes in the
uterus including reduced uterine volume,
endometrial and myometrial atrophy, uterine
fibrosis, loss of elasticity of the myometrium,
and reduced blood flow.
- Radiotherapy-induced structural and functional
changes to the uterus may adversely affect
implantation and maintenance of pregnancy
increasing the risk of placental attachment
disorders (placenta acreta or placenta percreta),
low birth weight (RR: 1.85, p = 0.03 in patients
treated with pelvic irradiation, and ORs from
3.64, 95 % CI: 1.33-9.96 in survivors after
abdominopelvic radiation up to 6.8, 95 % CI: 2.1-
22.2 in patients treated with high-dose (>5 Gy)
radiotherapy to the uterus), small for gestational
age (OR: 4.0, 85 % CI: 1.6-9.8 in patients treated
with high-dose (>5 Gy) radiotherapy to the
uterus), preterm delivery (OR: 3.5, 95 % CI: 1.5-8.0
in patients treated with high-dose (>5 Gy)
radiotherapy to the uterus), perinatal death, and
fetal malposition (for review, see Wo and
Viswanathan [60]).
- Surgical removal of the uterine cervix in
cervical cancer patients is associated with
increased risk of second trimester loss (10 % of
pregnancies) and premature delivery in the third
trimester (19 % of pregnancies) (for review, see
Knopman et al. [4]).
Musculoskeletal deficiencies in survivors of
childhood cancer (for reviews, see Wasilewski et
al. [63], Barnes and Chemaitilly [2], and Wissing
[64]).
- Low bone mineral density - A deficit in bone mineral density is associated
with increased susceptibility to fragility fractures
in pregnancy or the puerperium that may result
from the combination of abnormal skeletal
microarchitecture prior to pregnancy and
increased bone resorption during pregnancy (for
review, see Kovacs [65]).
- During pregnancy and lactation, calcium
homeostasis is overwhelmingly in favor of the
fetus/neonate, and the fetal/neonatal calcium
levels are maintained despite or even at the
expense of maternal levels and health (for
review, see Done [66]).
aORs, HRs, PRs, or RRs to mothers and offspring of some morbid conditions linked to prior anticancer treatments are missing because of reviewed data come from
literature narrative syntheses
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